Apremilast (BioDeep_00000663246)
代谢物信息卡片
Apremilast
化学式: C22H24N2O7S (460.1304154)
中文名称: 阿普斯特
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC1=C(C=CC(=C1)C(CS(=O)(=O)C)N2C(=O)C3=C(C2=O)C(=CC=C3)NC(=O)C)OC
InChI: InChI=1S/C22H24N2O7S/c1-5-31-19-11-14(9-10-18(19)30-3)17(12-32(4,28)29)24-21(26)15-7-6-8-16(23-13(2)25)20(15)22(24)27/h6-11,17H,5,12H2,1-4H3,(H,23,25)/t17-/m1/s1
描述信息
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants
D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058988 - Phosphodiesterase 4 Inhibitors
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, Guide to PHARMACOLOGY
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor
D000893 - Anti-Inflammatory Agents
D018501 - Antirheumatic Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:78540
- KEGGdrug: D08860
- PubChem: 11561674
- DrugBank: DB05676
- ChEMBL: CHEMBL514800
- CAS: 608141-41-9
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Ju Zhang, Yixuan Li, Jing Wang, Huan Jiang, Jiaping Qi, Chen Li, Zhenhua Ying. Is apremilast a treatment for SAPHO syndrome?.
The Journal of dermatological treatment.
2024 Dec; 35(1):2300743. doi:
10.1080/09546634.2023.2300743. [PMID: 38230420] - Maria C Schneeweiss, Denys Shay, Sophia Ly, Richard Wyss, Sebastian Schneeweiss, Robert J Glynn, Arash Mostaghimi. Prevalence of Pretreatment Testing Recommended for Patients With Chronic Inflammatory Skin Diseases.
JAMA dermatology.
2024 Mar; 160(3):334-340. doi:
10.1001/jamadermatol.2023.5895. [PMID: 38294794] - Melinda J Gooderham, H Chih-Ho Hong, Ivan V Litvinov. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
Skin therapy letter.
2022 11; 27(6):1-5. doi:
". [PMID: 36469536] - Dongkui Sui, Hua Yu. Protective roles of apremilast via Sirtuin 1 in atherosclerosis.
Bioengineered.
2022 05; 13(5):13872-13881. doi:
10.1080/21655979.2022.2085390. [PMID: 35707830] - Ivan Arias de la Rosa, Maria Dolores López-Montilla, Cristobal Román-Rodríguez, Carlos Pérez-Sánchez, Ignacio Gómez-García, Clementina López-Medina, Maria Lourdes Ladehesa-Pineda, Maria Del Carmen Ábalos-Aguilera, Desiree Ruiz, Alejandra Maria Patiño-Trives, Maria Luque-Tévar, Isabel Añón-Oñate, Maria Jose Pérez-Galán, Rocio Guzmán-Ruiz, Maria M Malagón, Chary López-Pedrera, Alejandro Escudero-Contreras, Eduardo Collantes-Estévez, Nuria Barbarroja. The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.
Journal of internal medicine.
2022 05; 291(5):676-693. doi:
10.1111/joim.13447. [PMID: 35233860] - Lyn D Ferguson, Susanne Cathcart, Dominic Rimmer, Gary Semple, Katriona Brooksbank, Caron Paterson, Rosemary Brown, John Harvie, Xuan Gao, Aleksandra Radjenovic, Paul Welsh, Iain B McInnes, Naveed Sattar, Stefan Siebert. Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study.
Rheumatology (Oxford, England).
2022 03; 61(3):1026-1034. doi:
10.1093/rheumatology/keab474. [PMID: 34097014] - Y Lytvyn, J R Georgakopoulos, A Mufti, A R Devani, M J Gooderham, V Jain, P Lansang, R Vender, V H Prajapati, J Yeung. Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study.
Journal of the European Academy of Dermatology and Venereology : JEADV.
2022 Feb; 36(2):e94-e95. doi:
10.1111/jdv.17749. [PMID: 34657332] - S M A Ahmed, M Volontè, E Isoletta, C Vassallo, C F Tomasini, D Lilleri, P Zelini, V Musella, C Klersy, V Brazzelli. SARS-CoV-2 serology in patients on biological therapy or apremilast for psoriasis: a study of 93 patients in the Italian red zone.
Journal of the European Academy of Dermatology and Venereology : JEADV.
2022 Feb; 36(2):e86-e88. doi:
10.1111/jdv.17721. [PMID: 34606128] - Yukari Okubo, Mamitaro Ohtsuki, Mayumi Komine, Shinichi Imafuku, Nastya Kassir, Rosemary Petric, Osamu Nemoto. Population pharmacokinetic and exposure-response analysis of apremilast in Japanese subjects with moderate to severe psoriasis.
The Journal of dermatology.
2021 Nov; 48(11):1652-1664. doi:
10.1111/1346-8138.16068. [PMID: 34396569] - A Pacifico, A d'Arino, P D M Pigatto, P Malagoli, Young Dermatologists Italian Network, G Damiani. COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast.
Clinical and experimental dermatology.
2021 10; 46(7):1344-1346. doi:
10.1111/ced.14723. [PMID: 33969530] - Vamshi Krishna Rapalli, Swati Sharma, Aniruddha Roy, Gautam Singhvi. Design and dermatokinetic evaluation of Apremilast loaded nanostructured lipid carriers embedded gel for topical delivery: A potential approach for improved permeation and prolong skin deposition.
Colloids and surfaces. B, Biointerfaces.
2021 Oct; 206(?):111945. doi:
10.1016/j.colsurfb.2021.111945. [PMID: 34216849] - Pim Aarts, Koen Dudink, Allard R J V Vossen, Kelsey R van Straalen, Christine B Ardon, Errol P Prens, Hessel H van der Zee. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
Drugs.
2021 Aug; 81(12):1397-1410. doi:
10.1007/s40265-021-01566-2. [PMID: 34283386] - Hanako Koguchi-Yoshioka, Rei Watanabe, Yutaka Matsumura, Yosuke Ishitsuka, Sae Inoue, Junichi Furuta, Yoshiyuki Nakamura, Naoko Okiyama, Takashi Matsuzaka, Hitoshi Shimano, Yasuhiro Fujisawa, Manabu Fujimoto. Serum lactate dehydrogenase level as a possible predictor of treatment preference in psoriasis.
Journal of dermatological science.
2021 Aug; 103(2):109-115. doi:
10.1016/j.jdermsci.2021.07.007. [PMID: 34332850] - Donovan G Kearns, Shelley Uppal, Vipawee S Chat, Jashin J Wu. Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.
Journal of drugs in dermatology : JDD.
2021 May; 20(5):582-583. doi:
10.36849/jdd.5730. [PMID: 33938697] - O G Artamonova, A E Karamova, A A Nikonorov, D A Verbenko, E L Vasileva, A A Kubanov. The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
Bulletin of experimental biology and medicine.
2021 May; 171(2):208-211. doi:
10.1007/s10517-021-05196-2. [PMID: 34173094] - M Talamonti, L Tofani, L Bianchi, M Galluzzo. Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?.
Archives of dermatological research.
2021 03; 313(2):127-128. doi:
10.1007/s00403-020-02103-z. [PMID: 32647977] - Pankaj Bansal, Amandeep Goyal, Austin Cusick, Fawad Aslam. Use of Apremilast in Patients With Psoriatic Arthritis During the COVID-19 Pandemic: Comment on the Article by Mikuls et al.
Arthritis & rheumatology (Hoboken, N.J.).
2021 03; 73(3):547-548. doi:
10.1002/art.41575. [PMID: 33142038] - Shinichi Imafuku, Osamu Nemoto, Yukari Okubo, Mayumi Komine, Peter Schafer, Rosemary Petric, Mamitaro Ohtsuki. Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial.
The Journal of dermatology.
2021 Jan; 48(1):80-84. doi:
10.1111/1346-8138.15596. [PMID: 32909643] - Susana Armesto, Carmen González Vela, Julia Sánchez, Aitziber Illaro, Jesús Mayorga, Ana E López Sundh, Cristina Naharro Fernández, Natalia Palmou, Cristina Gómez-Fernández, Marcos A González López, Miguel A González-Gay. Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic.
Dermatologic therapy.
2020 11; 33(6):e14464. doi:
10.1111/dth.14464. [PMID: 33112014] - Chirag A Shah. Can roflumilast become steroid-sparing alternative in the treatment of COVID-19?.
Medical hypotheses.
2020 Nov; 144(?):110246. doi:
10.1016/j.mehy.2020.110246. [PMID: 33254551] - Rubén Queiro Silva, Susana Armesto, Carmen González Vela, Cristina Naharro Fernández, Miguel Angel González-Gay. COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.
Dermatologic therapy.
2020 11; 33(6):e13961. doi:
10.1111/dth.13961. [PMID: 32618402] - V Venerito, D Natuzzi, R Bizzoca, N Lacarpia, F Cacciapaglia, G Lopalco, F Iannone. Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast.
Clinical and experimental immunology.
2020 08; 201(2):200-204. doi:
10.1111/cei.13451. [PMID: 32383167] - C Mugheddu, L Pizzatti, S Sanna, L Atzori, F Rongioletti. COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
Journal of the European Academy of Dermatology and Venereology : JEADV.
2020 Aug; 34(8):e376-e378. doi:
10.1111/jdv.16625. [PMID: 32385859] - Olga Yu Olisova, Ekaterina M Anpilogova, Dariya A Svistunova. Apremilast as a potential treatment option for COVID-19: No symptoms of infection in a psoriatic patient.
Dermatologic therapy.
2020 07; 33(4):e13668. doi:
10.1111/dth.13668. [PMID: 32449265] - Susana Armesto, Carmen González Vela, Marco Antonio González López. Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.
Dermatologic therapy.
2020 Jul; 33(4):e13618. doi:
10.1111/dth.13618. [PMID: 32424891] - Jorge R Georgakopoulos, Ron Vender, Jensen Yeung. Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice.
Journal of cutaneous medicine and surgery.
2020 Jul; 24(4):418-419. doi:
10.1177/1203475420928382. [PMID: 32396018] - Daniele Melis, Cristina Mugheddu, Silvia Sanna, Laura Atzori, Franco Rongioletti. Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.
Dermatologic therapy.
2020 Jul; 33(4):e13722. doi:
10.1111/dth.13722. [PMID: 32475036] - Jyotsana R Madan, Shweta Khobaragade, Kamal Dua, Rajendra Awasthi. Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast.
Dermatologic therapy.
2020 05; 33(3):e13370. doi:
10.1111/dth.13370. [PMID: 32250507] - Yifan Fu, Xiaoyu Ding, Xianglei Zhang, Xingcheng Shao, Jihui Zhao, Yechun Xu, Xiaomin Luo, Weimin Zhao. Diterpenoids from the Root Bark of Pinus massoniana and Evaluation of Their Phosphodiesterase Type 4D Inhibitory Activity.
Journal of natural products.
2020 04; 83(4):1229-1237. doi:
10.1021/acs.jnatprod.9b01269. [PMID: 32100544] - Irina V Medvedeva, Matthew E Stokes, Dominic Eisinger, Samuel T LaBrie, Jing Ai, Matthew W B Trotter, Peter Schafer, Robert Yang. Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects.
Scientific reports.
2020 01; 10(1):605. doi:
10.1038/s41598-020-57542-5. [PMID: 31953524] - Bruce Strober, Ali Alikhan, Benjamin Lockshin, Rebecca Shi, Joshua Cirulli, Peter Schafer. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study.
Journal of dermatological science.
2019 Dec; 96(3):126-133. doi:
10.1016/j.jdermsci.2019.09.003. [PMID: 31787506] - Geetika Chhabra, Prashant Verma. Steroid-resistant alopecia totalis in a child successfully treated with oral apremilast and platelet-rich plasma therapy.
Dermatologic therapy.
2019 11; 32(6):e13082. doi:
10.1111/dth.13082. [PMID: 31495982] - Michio Tokuyama, Tomomichi Shimizu, Takahiko Yamada, Akio Kondoh, Tomotaka Mabuchi. Case of psoriasis vulgaris with atrial fibrillation, heart failure and chronic kidney disease which were found accidentally through blood examination during apremilast treatment.
The Journal of dermatology.
2019 07; 46(7):e239-e240. doi:
10.1111/1346-8138.14784. [PMID: 30663127] - Faisal Imam, Naif O Al-Harbi, Mohammed M Al-Harbi, Wajhul Qamar, Khaldoon Aljerian, Osamah Mohammed Belali, Sary Alsanea, Ahmed Z Alanazi, Khalid Alhazzani. Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries.
International immunopharmacology.
2019 Jan; 66(?):260-266. doi:
10.1016/j.intimp.2018.11.023. [PMID: 30500623] - Carlo Pincelli, Peter H Schafer, Lars E French, Matthias Augustin, James G Krueger. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.
Journal of drugs in dermatology : JDD.
2018 Aug; 17(8):835-840. doi:
NULL. [PMID: 30124722] - Yuri A Blednov, Adriana J Da Costa, Tamara Tarbox, Olga Ponomareva, Robert O Messing, R Adron Harris. Apremilast Alters Behavioral Responses to Ethanol in Mice: I. Reduced Consumption and Preference.
Alcoholism, clinical and experimental research.
2018 05; 42(5):926-938. doi:
10.1111/acer.13616. [PMID: 29469962] - Dana Perrone, Faraz Afridi, Kelli King-Morris, Ashwini Komarla, Pran Kar. Proximal Renal Tubular Acidosis (Fanconi Syndrome) Induced by Apremilast: A Case Report.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2017 Nov; 70(5):729-731. doi:
10.1053/j.ajkd.2017.06.021. [PMID: 28823583] - Yong Liu, Simon Zhou, Mahmoud Assaf, Jim Nissel, Maria Palmisano. Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12.
Clinical pharmacology in drug development.
2016 Nov; 5(6):469-479. doi:
10.1002/cpdd.256. [PMID: 27870479] - Meiqiong Tang, Ping Hu, Shigui Huang, Qiang Zheng, Hao Yu, Yun He. Development of an Extended-Release Formulation for Apremilast and a Level A in Vitro-in Vivo Correlation Study in Beagle Dogs.
Chemical & pharmaceutical bulletin.
2016 Nov; 64(11):1607-1615. doi:
10.1248/cpb.c16-00519. [PMID: 27568485] - Faisal Imam, Naif O Al-Harbi, Mohammad Matar Al-Harbi, Mushtaq Ahmad Ansari, Mashal M Almutairi, Musaad Alshammari, Talal Saad Almukhlafi, Mohd Nazam Ansari, Khaldoon Aljerian, Sheikh Fayaz Ahmad. Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats.
Toxicology mechanisms and methods.
2016 Nov; 26(9):700-708. doi:
10.1080/15376516.2016.1236425. [PMID: 27785949] - Lian-Guo Chen, Zhe Wang, Shujun Wang, Tao Li, Yongyang Pan, Xixi Lai. Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study.
Journal of chromatographic science.
2016 Sep; 54(8):1336-40. doi:
10.1093/chromsci/bmw072. [PMID: 27165568] - Peter H Schafer, Peng Chen, Lorraine Fang, Andrew Wang, Rajesh Chopra. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1).
Journal of immunology research.
2015; 2015(?):906349. doi:
10.1155/2015/906349. [PMID: 25973439] - Jeff Sigler. Drug updates and approvals: 2014 in review.
The Nurse practitioner.
2014 Dec; 39(12):14-23; quiz 23. doi:
10.1097/01.npr.0000456393.83499.90. [PMID: 25350291] - Ejaz Pathan, Sonya Abraham, Elizabeth Van Rossen, Robin Withrington, Andrew Keat, Peter J Charles, Erin Paterson, Muslima Chowdhury, Catherine McClinton, Peter C Taylor. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
Annals of the rheumatic diseases.
2013 Sep; 72(9):1475-80. doi:
10.1136/annrheumdis-2012-201915. [PMID: 22984171] - Cho-Ming Loi, Dennis A Smith, Deepak Dalvie. Which metabolites circulate?.
Drug metabolism and disposition: the biological fate of chemicals.
2013 May; 41(5):933-51. doi:
10.1124/dmd.112.050278. [PMID: 23454828] - Matthew Hoffmann, Gondi Kumar, Peter Schafer, Dorota Cedzik, Lori Capone, Kei-Lai Fong, Zheming Gu, Dennis Heller, Hao Feng, Sekhar Surapaneni, Oscar Laskin, Anfan Wu. Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
Xenobiotica; the fate of foreign compounds in biological systems.
2011 Dec; 41(12):1063-75. doi:
10.3109/00498254.2011.604745. [PMID: 21859393]